DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

Market Cap	149.54B
Revenue (ttm)	243.74B
Net Income (ttm)	-3.04B
Shares Out	27.04M
EPS (ttm)	-111.93
PE Ratio	n/a
Forward PE	n/a
Dividend	120.00 (2.17%)
Ex-Dividend Date	Dec 27, 2024

Volume	77,601
Average Volume	78,833
Open	5,710.00
Previous Close	5,700.00
Day's Range	5,480.00 - 5,710.00
52-Week Range	4,300.00 - 8,990.00
Beta	0.74
RSI	44.01
Earnings Date	Aug 11, 2025

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 393
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.